



# Report Card on provincial formulary reimbursement listings for biologic response modifiers

## Go straight to your province or territory:

Alberta	Nunavut
British Columbia	Ontario
Manitoba	Prince Edward Island
New Brunswick	Quebec
Newfoundland and Labrador	Saskatchewan
Nova Scotia	Yukon Territory
Northwest Territories	

## Biologic Chart : Updated October 2007

Generic Name (Brand Name)	abatacept (Orencia®)	adalimumab (Humira®)	anakinra (Kineret®)	etanercept (Enbrel®)	infliximab (Remicade®)	rituximab (Rituxan®)	
<b>Alberta formulary</b>							Grade C-
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listed - CBC	Listed - CBC	Listed - CBC	Under review since Apr 2007	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Declined listing	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Listed - CBC	Not applicable	Listed - CBC	Under review, start date unknown	Not applicable	
<b>British Columbia formulary</b>							Grade: F
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Declined listing	Listed - CBC	Listed - CBC	Under review since Feb 2007	
Ankylosing Spondylitis	Not applicable	Under review since Nov 2006	Not applicable	Under review since May 2005	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Under review since Jul 2006	Not applicable	Listed - CBC Length of review, 3 years	Under review since Feb 2007	Not applicable	
<b>Manitoba formulary</b>							Grade: F
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listed - CBC	Listed - CBC	Listed - CBC	Under review since Mar 2007	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Listing status unknown	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Under review, start date unknown	Not applicable	Listing status unknown	Under review, start date unknown	Not applicable	

# Biologic Chart : Updated October 2007

Generic Name (Brand Name)	abatacept (Orencia®)	adalimumab (Humira®)	anakinra (Kineret®)	etanercept (Enbrel®)	infliximab (Remicade®)	rituximab (Rituxan®)	
<b>New Brunswick formulary</b>							Grade: C+
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listing status unknown	Listed - CBC	Listed - CBC	Listed - CBC	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Listed - CBC	Listed - CBC	Not applicable	
Psoriatic Arthritis	In clinical trials	Listed - CBC	Not applicable	Listed - CBC	Under review, start date unknown	Not applicable	
<b>Newfoundland and Labrador formulary</b>							Grade: C-
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listing status unknown	Listed - CBC	Listed - CBC	Listed - CBC	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Listing status unknown	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Listed - CBC	Not applicable	Listed - CBC	Under review, start date unknown	Not applicable	
<b>Nova Scotia formulary</b>							Grade: C-
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listing status unknown	Listed - CBC	Listed - CBC	Listed - CBC	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Listing status unknown	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Listed - CBC	Not applicable	Listed - CBC	Under review, start date unknown	Not applicable	
<b>Northwest Territories formulary</b>							Grade: F
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listing status unknown	Listed - CBC	Listed - CBC	Listed - CBC	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Under review, start date unknown	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Under review, start date unknown	Not applicable	Under review, start date unknown	Under review, start date unknown	Not applicable	

# Biologic Chart : Updated October 2007

Generic Name (Brand Name)	abatacept (Orencia®)	adalimumab (Humira®)	anakinra (Kineret®)	etanercept (Enbrel®)	infliximab (Remicade®)	rituximab (Rituxan®)	
<b>Nunavut formulary</b>							Grade: F
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listing status unknown	Listed - CBC	Listed - CBC	Under review since Mar 2007	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Listing Status unknown	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Under review, start date unknown	Not applicable	Listing Status unknown	Under review, start date unknown	Not applicable	
<b>Ontario formulary</b>							Grade: B
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listed - CBC	Listed - CBC	Listed - CBC	Listed - CBC	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Listed - CBC	Listed - CBC	Not applicable	
Psoriatic Arthritis	In clinical trials	Listed - CBC	Not applicable	Listed - CBC	Under review, start date unknown	Not applicable	
<b>Prince Edward Island formulary</b>							Grade: F
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listing status unknown	Listed - CBC	Listed - CBC	Under review since Feb 2007	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Under review, start date unknown	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Under review, start date unknown	Not applicable	Under review, start date unknown	Under review, start date unknown	Not applicable	
<b>Quebec formulary</b>							Grade: B+
Rheumatoid Arthritis	Listed - CBC	Listed - CBC	Listing status unknown	Listed - CBC	Listed - CBC	Declined listing	
Ankylosing Spondylitis	Not applicable	Listed - CBC	Not applicable	Listed - CBC	Listed - CBC	Not applicable	
Psoriatic Arthritis	In clinical trials	Listed - CBC	Not applicable	Listed - CBC	Listed - CBC	Not applicable	

# Biologic Chart : Updated October 2007

Generic Name (Brand Name)	abatacept (Orencia®)	adalimumab (Humira®)	anakinra (Kineret®)	etanercept (Enbrel®)	infliximab (Remicade®)	rituximab (Rituxan®)	
<b>Saskatchewan formulary</b>							Grade: C
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listed - CBC	Listed - CBC	Listed - CBC	Under review since Apr 2007	
Ankylosing Spondylitis	Not applicable	Declined listing	Not applicable	Declined listing	Declined listing	Not applicable	
Psoriatic Arthritis	In clinical trials	Listed - CBC	Not applicable	Listed - CBC	Declined listing	Not applicable	
<b>Yukon Territory formulary</b>							Grade: D
Rheumatoid Arthritis	Under review since Jul 2007	Listed - CBC	Listing status unknown	Listed - CBC	Listed - CBC	Listed - CBC	
Ankylosing Spondylitis	Not applicable	Under review, start date unknown	Not applicable	Under review, start date unknown	Under review since Jul 2005	Not applicable	
Psoriatic Arthritis	In clinical trials	Listed - CBC	Not applicable	Under review, start date unknown	Under review, start date unknown	Not applicable	

## Legend

**Under review** means that this drug has been approved by Health Canada and the province is currently deciding whether or not to reimburse for this drug.

**In clinical trials** means that this medication is undergoing testing for use in treating this disease type.

**Listing status unknown** means there is no public information available

**Declined listing** means that the formulary has decided not to reimburse patients being prescribed this medication.

**Case by case (or CBC)** Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). For the purposes of this report card, we have referred to these as case by case (or CBC) approvals.

**Not applicable** means that no Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.

## Letter grades

Arthritis Consumer Experts graded each of the provinces by assigning a score based upon number of medications listed, number under review, and number of declined listings. The scores were then translated into letter grades.

**Note:** in some cases, information was unavailable from a province or territory's website. This lack of transparency was reflected in grade assignments.

**Because provincial formularies change frequently, we encourage you to contact the Ministry of Health in your province with questions you may have about medication listings of concern to you.**